Swedish drugmaker Recipharm said it has begun manufacturing a chloroquine phosphate product in anticipation of increased demand during the coronavirus pandemic.

The company is also developing a new product with hydroxychloroquine as the active pharmaceutical ingredient.

There is “a great need for more clinical evidence regarding the use of chloroquine, but we also need to prepare for the event that it could be identified as an effective part of COVID-19 treatment,” the company said.